Company / Working Capital
Bristol Myers Squibb Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$6.0B
FY2025
5-year range
$5.4B / $11.4B
FY2021-FY2025
Trend
-0.5%
vs FY2024
Sector context
#6 of 213
Health Care
What the data says
Among 213 Health Care companies, Bristol Myers Squibb is in the top 3% for working capital. Working Capital has fluctuated over the past 10 years, ranging from $4.9B in FY2016 to $11.4B in FY2021.
Based on SEC 10-K filings.
$6.0B in FY2025 with a 5-year CAGR of -11.7%. Top quartile in the Health Care sector.
Declined from $9.5B to $6.0B over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +3.5%
- 5-Year CAGR
- -11.7%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 213This company $6.0B Sector average $934.6M
▼
+539.1% above sector average
Key checks
Key Insights
- 5-year CAGR of -11.7%, indicating a declining trend.
- In FY2025, working capital decreased 0.5% year-over-year.
- Ranks #6 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.0B | -0.5% |
| FY2024 | $6.0B | -36.8% |
| FY2023 | $9.5B | +76.6% |
| FY2022 | $5.4B | -52.8% |
| FY2021 | $11.4B | +2.5% |
| FY2020 | $11.1B | +0.6% |
| FY2019 | $11.1B | +69.8% |
| FY2018 | $6.5B | +23.0% |
| FY2017 | $5.3B | +8.8% |
| FY2016 | $4.9B | +102.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026